期刊文献+

PDCA循环管理法持续改进门诊氯吡格雷使用评价 被引量:1

Continuous Improvement of Rational Use of Clopidogrel in Outpatient Department by PDCA Cycle Management
下载PDF
导出
摘要 目的运用PDCA循环管理持续改进门诊氯吡格雷使用的合理性,探讨促进临床合理用药的方法。方法临床药师用PDCA循环管理对氯吡格雷在门诊使用进行4个阶段的干预,并结合说明书与权威指南,参与制订《芜湖市第二人民医院氯吡格雷合理用药评价细则》,为临床提供抗血小板治疗方案;在管理过程中发现问题并找出解决措施,加强与临床医师与患者的沟通;通过比较干预前阶段与干预后4个阶段氯吡格雷处方合格率,评价PDCA管理法在规范用药合理性中发挥的作用。结果经过4阶段PDCA循环后,门诊氯吡格雷处方合格率从干预前的95.37%提高至99.68%;存在的主要不合理问题如适应症不适宜、联合抗血小板无指征、用法用量不适宜及未从经济学原则选用药物较干预前均明显减少。结论PDCA循环管理可提高门诊氯吡格雷使用合理性,临床药师参与其中可提高临床合理用药水平。 Objective To continuously improve the rational use of clopidogrel in outpatient department by PDCA cycle management,and to explore the methods for promotion of the rational use of drugs in clinical practice.Methods Clinical pharmacists used PDCA cycle management to intervene the use of clopidogrel in outpatient department in four stages.Combined with instructions and authoritative guidance,clinical pharmacists participated in the formulation of“Detailed Rules for Evaluation of Rational Use of Clopidogrel in the Second People’s Hospital of Wuhu”to provide anti-platelet treatment programs for clinic.In the management process,the problems were identified and the solutions were found,and the communication with clinicians and patients were strengthened.By comparing the qualified rate of the prescriptions in the pre-intervention stage and the four post-intervention stages,the role of PDCA management in regulating the rationality of drug use was evaluated.Results After the four-stage PDCA cycle,the qualified rate of the prescriptions in outpatient department increased from 95.37% to 99.68%.The main problems such as inappropriate indications,no indication for combination with anti-platelet treatment,inappropriate usage and dosage,and selection of drug not from economic principles before intervention were significantly reduced.Conclusion PDCA cycle management can improve the rationality of clopidogrel use in outpatient department,and the participation of clinical pharmacists can improve the level of clinical rational drug use.
作者 张晓明 林彤远 陈斌 荀艳 ZHANG Xiao-ming;LIN Tong-yuan;CHEN Bin;XUN Yan(Pharmacy Department,The Second People’s Hospital of Wuhu,Wuhu 241000,China)
出处 《食品与药品》 CAS 2020年第1期64-67,共4页 Food and Drug
基金 2018年中华医学会临床药学分会-吴阶平基金会科研基金(基金号:LCYX-Q010)。
关键词 PDCA循环管理法 临床药师 氯吡格雷 处方 合格率 PDCA circulation management method clinical pharmacist clopidogrel prescription qualified rate
  • 相关文献

参考文献11

二级参考文献107

  • 1贾国强,张信红.新型的ADP受体拮抗剂--硫酸氢氯吡格雷[J].中国药物应用与监测,2002(5):52-53. 被引量:9
  • 2陈健华,王建明,崔丽英,陈琳.阿司匹林与脑出血危险性的关系[J].中风与神经疾病杂志,2007,24(2):196-198. 被引量:25
  • 3卫生部.医疗机构药事管理规定[S].2011.
  • 4卫生部.糖皮质激素类药物临床应用指导原则[S].2011-02-16.
  • 5陈灏珠,林果为,王吉耀实用内科学[M].14版北京:人民卫生出版社:2013:9.
  • 6McClung JA, Kruger AL, Ferraris A, et al, Usefulness of clopidogrelto protect anainst diabetes-induced vascular damage[J]. Am J Cardiol, 2010, 105(7): 1014-1018.
  • 7Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes:the Global Registry of Acute Coronary Events(GRACE)[J]. Eur Heart J, 2003, 24(20): 1815-1823.
  • 8Uchiyama S, Tanahashi N, Minematsu K, et al. Clopidogrel two doses comparative 1-year assessment of safety and efficacy(COMPASS)study in Japanese patients with ischemic stroke[J]. Cerebrovasc Dis, 2012, 34(3): 229-239.
  • 9卫生部.三级综合医院评审标准实施细则:2011版[S].2011-12-25.
  • 10古丽加孜- 毛吾提汗.临床上西药发生不良反应的状况分析[J].综合医学,2013,10:271.

共引文献225

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部